Mangoceuticals, Inc. Announces Business Combination with Nuclea Energy; CEO Change

What Happened
Mangoceuticals, Inc. (MGRX) announced on July 29, 2026 that it entered into a Business Combination Agreement (BCA) to combine with Nuclea Energy Inc. via a Canadian exchangeable-share structure. Under the deal, Nuclea shareholders will receive exchangeable shares convertible one-for-one into Mango common stock through a subsidiary (ExchangeCo). Based on the stated exchange ratio (Fully Diluted Mango Shares / Fully Diluted Nuclea Shares × 24), prior to the PIPE issuance former Nuclea holders would hold roughly 96% of Mango on a fully diluted, as‑exchanged basis and existing Mango holders about 4%. The transaction contemplates a Closing expected before regulatory and Nasdaq approvals and a Completion that unlocks full exchange and voting rights after required approvals. A minimum $15.0 million PIPE will be escrowed and released at Closing. Management changes at Closing include appointment of Sagar Sanghera as Executive Chairman, Josef Freundorfer as CEO, and Jacob D. Cohen stepping down as CEO and becoming President under separation/consulting agreements.

Key Details

• Exchange structure: exchange ratio = (Fully Diluted Mango / Fully Diluted Nuclea) × 24; implies ~96% ownership for former Nuclea holders prior to PIPE.
• PIPE requirement: minimum $15,000,000 private investment in public equity to be funded into escrow and released at Closing.
• Nasdaq cap: economic, voting and exchange rights tied to Exchangeable Shares are limited to 19.99% of Mango common stock until both Mango stockholder approval and Nasdaq initial listing approval are obtained.
• Executive/separation terms for Jacob D. Cohen: $1,500,000 cash at Closing; 2,000,000 Mango shares upon signing; a $10,000,000 cashless warrant (issued at Completion); acceleration of unvested equity; 12 months COBRA; and a general release.
• Corporate governance: Bylaws amended July 28, 2026 to reduce shareholder-meeting quorum from majority to one‑third (1/3) of voting power.
• Transaction conditions include Nuclea shareholder approval, Nasdaq non‑objection, regulatory clearances (Canada/HSR), a second 180‑day Nasdaq bid-price grace period by Aug 3, 2026, and voting support agreements representing at least ~50.1% (9,119,823 shares) from Cohen and affiliates.

Why It Matters
This is a transformational deal that would substantially change Mangoceuticals’ ownership and control—former Nuclea holders are projected to own the vast majority of the company on a fully diluted basis before the PIPE. The $15M PIPE is material financing but must close for the deal to proceed; until Nasdaq and shareholder approvals are obtained, Exchangeable Shares are capped at 19.99% voting/economic rights, limiting immediate control shifts. Management turnover and the sizable separation package for the current CEO are important corporate governance developments. The bylaw quorum reduction can affect how easily shareholder votes are obtained in the future. Investors should watch the PIPE completion, shareholder and Nasdaq approvals, regulatory clearances, and the S-4/proxy filing for final terms and dilution details.